ATE352784T1 - Verfahren zum screenen für gpr40-liganden - Google Patents

Verfahren zum screenen für gpr40-liganden

Info

Publication number
ATE352784T1
ATE352784T1 AT01994292T AT01994292T ATE352784T1 AT E352784 T1 ATE352784 T1 AT E352784T1 AT 01994292 T AT01994292 T AT 01994292T AT 01994292 T AT01994292 T AT 01994292T AT E352784 T1 ATE352784 T1 AT E352784T1
Authority
AT
Austria
Prior art keywords
screening
ligands
gpr40
gpr40 ligands
methods
Prior art date
Application number
AT01994292T
Other languages
English (en)
Inventor
John Leon Andrews
Celia Patricia Briscoe
Diane Michelle Ignar
Alison Isobel Muir
Howard Ray Sauls Jr
Mohammad Tadayyon
Original Assignee
Glaxo Group Ltd
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Smithkline Beecham Plc filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE352784T1 publication Critical patent/ATE352784T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT01994292T 2000-12-22 2001-12-18 Verfahren zum screenen für gpr40-liganden ATE352784T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0031527.5A GB0031527D0 (en) 2000-12-22 2000-12-22 New use

Publications (1)

Publication Number Publication Date
ATE352784T1 true ATE352784T1 (de) 2007-02-15

Family

ID=9905799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994292T ATE352784T1 (de) 2000-12-22 2001-12-18 Verfahren zum screenen für gpr40-liganden

Country Status (7)

Country Link
EP (1) EP1354200B1 (de)
AT (1) ATE352784T1 (de)
AU (1) AU2002246702A1 (de)
DE (1) DE60126337T2 (de)
ES (1) ES2280427T3 (de)
GB (1) GB0031527D0 (de)
WO (1) WO2002057783A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214495B2 (en) 2002-02-14 2007-05-08 Takeda Pharmaceutical Company Limited Screening method
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004050853A2 (en) * 2002-12-04 2004-06-17 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
JP4574177B2 (ja) * 2003-01-17 2010-11-04 武田薬品工業株式会社 新規スクリーニング方法
ATE511644T1 (de) 2003-01-17 2011-06-15 Takeda Pharmaceutical Neues screening-verfahren
WO2004072650A1 (en) * 2003-02-17 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005015990A1 (en) * 2003-08-18 2005-02-24 Betagenon Ab New diabetes type 2 animal model
WO2005051890A1 (en) * 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1737809B1 (de) 2004-02-27 2013-09-18 Amgen, Inc Verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung bei der behandlung von stoffwechselstörungen
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
US20060003344A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP1953238B1 (de) * 2005-11-04 2011-12-21 Eisai R&D Management Co., Ltd. Verfahren zum Screening von Substanzen unter Verwendung von GPR40 und sekretierter Phospholipase A2
EP2061760A1 (de) 2006-09-07 2009-05-27 Amgen, Inc Benzokondensierte verbindungen zur verwendung bei der behandlung von stoffwechselerkrankungen
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルgpr40調節因子
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
PL233938B1 (pl) * 2018-01-08 2019-12-31 CELON PHARMA Spólka Akcyjna Pochodne kwasu 3-fenylo-4-heksynowego jako agoniści GPR40

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309854B1 (en) * 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1770159A1 (de) * 2000-12-01 2007-04-04 Astellas Pharma Inc. Verfahren zur Herstellung eines Arzneimittels zur Behandlung von Diabetes

Also Published As

Publication number Publication date
EP1354200B1 (de) 2007-01-24
DE60126337T2 (de) 2007-11-15
GB0031527D0 (en) 2001-02-07
ES2280427T3 (es) 2007-09-16
EP1354200A2 (de) 2003-10-22
WO2002057783A3 (en) 2003-08-07
WO2002057783A2 (en) 2002-07-25
AU2002246702A1 (en) 2002-07-30
DE60126337D1 (de) 2007-03-15

Similar Documents

Publication Publication Date Title
DE60126337D1 (de) Verfahren zum screenen für gpr40-liganden
DE50204719D1 (de) Verfahren zum bereitstellen von leistungsmerkmalen für alternativ-verbindungen von primär-verbindungen
DE50111437D1 (de) Verfahren zum einbringen von zuschlagstoffen (additiven)
ATA8612001A (de) Verfahren zum testen von software
DE60326760D1 (de) Verfahren zum verbinden
DE60020163D1 (de) Fotomaske, verfahren zu ihrer herstellung
DE60038856D1 (de) Herstellungsverfahren für Toner
EP1082289A4 (de) Methoden zur identifizierung neuer multimerer, rezeptor-modulierender substanzen
DE60116009D1 (de) Verfahren zum herstellen von reduziertem eisen
DE60132243D1 (de) Verfahren zum indizieren von entitäten
ATE230726T1 (de) Verfahren um diaryl-pyridine zu herstellen, die als cox-inhibitoren verwendbar sind
FI20002720A7 (fi) Menetelmä konversioiden suorittamiseksi
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
EP0791008A4 (de) Screeningmethode für verbindungen, die eine affinität zur rns haben
DE60317136D1 (de) Immuntestverfahren, Reagenz für Immuntestverfahren und Verfahren zu dessen Herstellung
DE60142344D1 (de) Schweiss-herstellungsverfahren für einen elektrolyseur
DE60314955D1 (de) Verfahren zur Inspektion von Dampfturbinen
DE50102671D1 (de) Diethyloctandioldicarbamate und diethyloctandioldiallophanate, verfahren zu ihrer herstellung und ihre verwendung
DE60044618D1 (de) Verfahren zum verbinden von strickwaren
DE602004022156D1 (de) Verfahren zum verbinden von strickwaren
ATE255820T1 (de) Verfahren zum pelletieren
DE60217621T8 (de) Verfahren für Kranbedienung
DE60023243D1 (de) Verfahren zum Erzeugen von gleichmässigem Glanz
EP1305625A4 (de) Verfahren zum immunnachweis von epitopen
ATE378307T1 (de) Verfahren zur gewinnung von cetamin-enantiomeren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties